- Home
- BCML vs RIGL Comparison
BCML vs RIGL Comparison
Compare BCML & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCML
- RIGL
- Stock Information
- Founded
- BCML 2004
- RIGL 1996
- Country
- BCML United States
- RIGL United States
- Employees
- BCML N/A
- RIGL N/A
- Industry
- BCML Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- BCML Finance
- RIGL Health Care
- Exchange
- BCML Nasdaq
- RIGL Nasdaq
- Market Cap
- BCML 279.0M
- RIGL 298.0M
- IPO Year
- BCML N/A
- RIGL 2000
- Fundamental
- Price
- BCML $25.98
- RIGL $16.85
- Analyst Decision
- BCML
- RIGL Buy
- Analyst Count
- BCML 0
- RIGL 5
- Target Price
- BCML N/A
- RIGL $36.80
- AVG Volume (30 Days)
- BCML 29.1K
- RIGL 248.5K
- Earning Date
- BCML 04-17-2025
- RIGL 05-06-2025
- Dividend Yield
- BCML 2.31%
- RIGL N/A
- EPS Growth
- BCML N/A
- RIGL N/A
- EPS
- BCML 2.10
- RIGL 0.99
- Revenue
- BCML $95,714,000.00
- RIGL $179,278,000.00
- Revenue This Year
- BCML $3.69
- RIGL $12.53
- Revenue Next Year
- BCML $6.03
- RIGL $15.68
- P/E Ratio
- BCML $12.38
- RIGL $17.02
- Revenue Growth
- BCML N/A
- RIGL 54.71
- 52 Week Low
- BCML $18.54
- RIGL $7.48
- 52 Week High
- BCML $30.13
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- BCML 54.00
- RIGL 41.36
- Support Level
- BCML $24.17
- RIGL $16.05
- Resistance Level
- BCML $26.25
- RIGL $17.67
- Average True Range (ATR)
- BCML 1.46
- RIGL 1.31
- MACD
- BCML 0.19
- RIGL 0.02
- Stochastic Oscillator
- BCML 78.66
- RIGL 45.76
About BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.